In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B

Diagnostic Microbiology and Infectious Disease

Volumn 33, Issue 1, 1999, Pages 7-11

  Abraham, O C ^a   Manavathu, Elias K ^a   Cutright, Jessica L ^a   Chandrasekar, Pranatharthi H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; DRUG RESISTANCE, MICROBIAL; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 0033011505     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00102-3     Document Type: Article

References (17)

1. Barry A.L., Brown S.D. In vitro studies of two triazole antifungal agents (Voriconazole [UK-109,496] and Fluconazole) against Candida species. Antimicrob Agents Chemother. 40:1996;1948-1949.
2. Denning D.W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 23:1996;608-615.
3. Denning D.W., Lee J.Y., Hostetler J.S., et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 97:1994;135-144.
4. Espinel-Ingroff A., Bartlett M., Bowden R., et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol. 35:1997;139-143.
5. Espinel-Ingroff A., Dawson K., Pfaller M.A., Anaisse E., Breslin B., Dixon D., Fothergill A., Paetznick V., Peter J., Rinaldi M., Walsh T. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother. 39:1995;314-319.
6. Espinel-Ingroff A. In vitro activity of the new triazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol. 36:1998;198-202.
7. Fraser D.W., Ward J.I., Ajello L., Plikaytis B.D. Aspergillosis and other systemic mycoses The growing problem . JAMA. 242:1979;1631-1635.
8. Kaufman C.A., Zarins L.T. In vitro activity of voriconazole against Candida species. Diagn Microbiol Infect Dis. 31:1998;297-300.
9. Manavathu EK, Alangaden GJ, Lerner SA (1995) Isolation and characterization of itraconazole-resistant mutants of Aspergillus fumigatus. Abstr. C101, p. 57. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC.
10. Manavathu E.K., Alangaden G.J., Lerner S.A. A comparative study of the broth micro- and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus. Can J Microbiol. 42:1996;960-964.
11. Manavathu E.K., Cutright J.L., Chandrasekar P.H. In vitro susceptibility of itraconazole-resistant isolates of Aspergillus fumigatus to voriconazole. Clin Microbiol Infect. 3:(suppl. 2):1997;81.
12. Marco F., Pfaller M.A., Messer S., Jones R.N. In vitro activities of Voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother. 42:1998;161-163.
13. Martin M.V., Yates J., Hitchcock C.A. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother. 41:1997;13-16.
14. McGinnis M.R., Pasarell L., Sutton D.A., Fothergill A.W., Cooper C.R. Jr, Rinaldi M.G. In vitro evaluation of Voriconazole against some clinically important fungi. Antimicrob Agents Chemother. 41:1997;1832-1834.
15. Murphy M., Bernard E.M., Ishimaru T., Armstrong D. Activity of Voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 41:1997;696-698.
16. Pujol I.Y., Guarro J., Llop C., Soler L., Fernandez-Ballart J. Comparison Study of Broth macrodilution and Microdilution Antifungal Susceptibility Tests for the Filamentous Fungi. Antimicrob Agents Chemother. 40:1996;2106-2110.
17. Radford S.A., Johnson E.M., Warnock D.W. In vitro studies of activity of Voriconazole (UK-109,496), a new triazole antifungal agent against emerging and less common mold pathogens. Antimicrob Agents Chemother. 41:1997;841-843.